学術情報 -AJRCCM(ブルージャーナル)-

本誌は、American Thoracic Society(米国胸部学会)の発行するAmerican Journal of Respiratory and Critical Care Medicineをもとに、シュプリンガー・ジャパン株式会社が公正中立の立場で論文選択、翻訳等を含む作業全般を担っている医療関係者向けの資材です。

弊社は、医療関係者に有益な情報を提供することを通じて医療に貢献することを目的に本資材の提供を行っており、本資材作成にかかる費用を負担しています。

本資材には本邦における未承認の医薬品、効能・効果及び用法・用量等の情報が含まれる場合がありますが、これを推奨するものではありません。

本資材を受領される際には、以下の内容をご確認いただきたく存じます。

  • 本資材に記載された薬剤の使用にあたっては、最新の添付文書をご参照ください。
  • 本資材は医療関係者からの求めに応じて提供するものであり、企業が積極的に提供するものではありません。

2019年07月 -PART 02-

環境大気汚染への短期曝露と喘息による死亡

Short-Term Exposure to Ambient Air Pollution and Asthma Mortality
Am J Respir Crit Care Med 2019; 200(1): 24‒32

プロテインホスファターゼ2Aはタバコ煙誘発性のカテプシンS発現と活性の増強及び肺機能低下を抑制する

Protein Phosphatase 2A Reduces Cigarette Smoke‒induced Cathepsin S and Loss of Lung Function
Am J Respir Crit Care Med 2019; 200(1): 51‒62

マウスにおいて肺胞マクロファージのアポトーシスに伴う殺菌作用は肺炎の予防に役立つ

Alveolar Macrophage Apoptosis‒associated Bacterial Killing Helps Prevent Murine Pneumonia
Am J Respir Crit Care Med 2019; 200(1): 84‒97

2019年07月 -PART 01-

オメガ-3及びオメガ-6脂肪酸摂取量は小児の喘息重症度及び室内空気汚染に対する反応に影響を与える

Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children
Am J Respir Crit Care Med 2019; 199(12): 1478‒1486

環境超微粒子と小児喘息の発症の関連性

Spatiotemporal Variations in Ambient Ultrafine Particles and the Incidence of Childhood Asthma
Am J Respir Crit Care Med 2019; 199(12): 1487‒1495

ヒトライノウイルスは慢性閉塞性肺疾患(COPD)患者の細菌に対する肺胞マクロファージの自然免疫反応を減弱させる

Human Rhinovirus Impairs the Innate Immune Response to Bacteria in Alveolar Macrophages in Chronic Obstructive Pulmonary Disease
Am J Respir Crit Care Med 2019; 199(12): 1496‒1507

Selected articles from AJRCCM. Copyright 2018 by the American Thoracic Society. All rights reserved. The ideas and opinions expressed in the American Journal of Respiratory and Critical Care Medicine (AJRCCM) or other associated publications do not necessarily reflect those of the American Thoracic Society (ATS). The authors, editors or ATS are not responsible for errors or omissions of articles published in print or online from AJRCCM or other associated ATS publications. Although great care has been taken in compiling the content of this publication, neither ATS or their servants are responsible or liable in any way for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising there from. Approved product information should be reviewed before prescribing. The mention of any product, service, or therapy in this publication should not be construed as an endorsement of the products mentioned. It is the responsibility of the treating physician or other health care provider, relying on independent experience and knowledge of the patient, to determine drug dosages and the best treatment for the patient. Readers are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each drug to be administered to verify the dosage, method, and duration of administration, or contraindications. Readers are also encouraged to contact the manufacturer with questions about the features or limitations of any products. ATS assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. 

The translation is © 2018 American Thoracic Society. American Thoracic Society or Springer Healthcare takes no responsibility for the accuracy of the translation from the published English original and are not liable for any errors that may occur.